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48
Staphylococcus aureus is a pathogenic bacterium that causes a wide range of human infections, 49 ranging from mild skin lesions to more invasive and life-threatening infections, such as bacteremia, 50 endocarditis, wound infections, and pneumonia. The pathogenesis of S. aureus infections is 51 generally attributed to a wide array of virulence determinants including surface proteins 1 and 52 glycopolymers 2 , as well as multiple secreted proteins, such as cytolysins, superantigens, 53 leukotoxins, hemolysins, and proteases 3 . Although several specific export pathways have been 54 described in S. aureus, the secretome often includes proteins that lack export signals and have 55 typical cytoplasmic functions. The mechanisms by which cytoplasmic proteins are excreted by 56
S. aureus has attracted recent interest 4, 5 , and there is increasing evidence that these proteins 57 may be secreted within membrane vesicles [6] [7] [8] [9] . 58
Secretion of extracellular vesicles (EVs) is a process common to eukaryotes, archae, and 59 bacteria 10 . EVs are nano-sized, spherical, bilayered membrane vesicles with a cargo that includes 60 diverse proteins, polysaccharides, nucleic acids, and lipids. EV formation by Gram-negative 61 bacteria was first observed by electron microscopy in the 1960s 11, 12 , and these bacteria secrete 62
what are now referred to as outer membrane vesicles (OMVs). The generation of OMVs appears 63 to occur by phospholipid accumulation in the outer leaflet of the outer membrane, followed by the 64 formation of outer membrane protrusions that pinch off to form vesicles 13 . OMVs likely play 65 important roles in bacterial pathogenesis due to packaging of multiple virulence factors 14 , and the 66 ability of OMVs to serve as immune modulators by inducing innate and adaptive immune 67 responses 15 .
68
More recent work has described the production and release of extracellular vesicles (EVs) 69 from Gram positive bacteria, such as S. aureus 16, 17 , attesting to the efficacy of this 85 vaccine platform. Additionally, a growing number of studies involving the use of OMVs as vaccines 86 against bacterial pathogens have shown protection in experimental infection models [22] [23] [24] [25] .
87
Despite repeated efforts to develop experimental vaccines and immunotherapeutics 88 against S. aureus, neither have proven effective in preventing staphylococcal infections in 89 humans 26 . Mice immunized with native EVs from S. aureus ATCC 14458 responded with a robust 90 T cell response and were protected against staphylococcal lung infections, although the cytolytic 91 activity of EVs prepared from wild type (WT) S. aureus was not addressed in this study 27 . Similarly, 92
EVs isolated from S. pneumoniae protected mice against lethal pneumonia 7 . Despite the 93 documented immunogenicity and protective efficacy of bacterial EV-based vaccines, EV 94 preparations derived from some bacterial pathogens may contain toxins or other virulence factors 95 that potentially damage host cells 17, [28] [29] [30] [31] . The development of EVs as a vaccine platform will 96 require a more thorough characterization of the mechanisms of EV biogenesis to allow for 97 consistent production with adequate quality assurance. 98 7 damaging activity of PSMs 5 . Because the cargo of S. aureus EVs is enriched for both lipoproteins 148 and cytoplasmic proteins, we evaluated whether PSM peptides were critical for EV generation. 149
We measured EV production by the WT USA300 LAC strain (the parent strain of JE2), as 150 well as LAC ∆psmα, ∆psmβ, and ∆psmα∆psmβ mutants 34 . First, we evaluated EV production by 151 dot immunoblot analysis with detection by serum from mice immunized with WT JE2 EVs. Only 152 mutation of psmα genes showed a reduced signal in immunoblotting assay for EV production (Fig.  153   2a) . To further substantiate our result, we measured EV yield and particle number by assays for 154 protein content and nanoparticle tracking, respectively. Consistently, mutation of the psmα genes 155 significantly reduced S. aureus EV yield (Fig. 2b ) and particle number (Fig. 2c) . The ∆psmα and 156 ∆psmα∆psmβ double mutant produced comparable levels of EVs when tested with EV yield 157 analysis (Fig. 2b) , indicating that PSMα peptides play the dominant role in this phenotype. 158
Complemention with p∆TX expressing PSMα1-4 genes, but not the p∆TX vector alone, restored 159 EV production to the ∆psmα mutant (Figs. 2b and 2c) . Mutation of the psmα genes significantly 160 reduced S. aureus EV size ( Fig. 2c and 2d ), whereas the ∆psmβ mutant produced EVs of 161 intermediate size compared to that of WT LAC. 162 PGN cross-linking modulates EVs production. Unlike OMVs produced by Gram-negative 163 microbes, S. aureus cytoplasmic membrane-derived EVs must traverse a PGN cell wall structure 164 before cellular release. To determine whether the degree of PGN crosslinking affected S. aureus 165 EV biogenesis, we cultured S. aureus JE2 in medium with a sublethal concentration (0.2 µg/ml) 166 of penicillin G (PenG) that has been shown to decrease PGN cross-linking 37 . Treatment with a 167 sublethal concentration (0.1 µg/ml) of Em served as antibiotic control that has no effect on PGN 168 cross-linking. Compared to EVs recovered from untreated cultures or cultures incubated with Em, 169 the EV yield from PenG-treated cultures was distinctly higher (Fig. 3a) . When the EV protein 170 content was quantified from a fixed volume of culture left untreated or treated with sublethal 171 8 antibiotic concentrations, we observed a 10-fold increase in EV yield from PenG-treated cultures 172 (Fig. 3b) . 173 S. aureus penicillin binding protein 4 (PBP4) is a carboxypeptidase that is essential for 174 secondary crosslinking of PGN, and a pbp4 mutant shows a significant reduction in PGN 175 crosslinking 37, 38 . As predicted, both dot blot (Fig. 3c) and EV protein yield assays (Fig. 3d) showed 176 increased EV production by JE2pbp4, and the protein yield was 3-fold higher than the wild-type 177 JE2 strain. We also measured EV production in MRSA isolates MW2, COL, and their ∆pbp4 178 mutants; the relative increase in EV yield in the mutant strains ( Fig. 3c and 3d JE2, COL, and Newman, tagO mutants showed an enhanced signal in the dot immunoblot assay 185 for EV production (Fig. 3e) . Likewise, quantitative analysis of EV protein yield showed that all 186 three tagO mutants produced significantly more EVs than the parental isolates (Fig. 3f) . Thus, 187
WTAs negatively modulate S. aureus EV production, consistent with reports showing that tagO 188 mutants are characterized by diminished PGN cross-linking 42 . The WTA backbone is decorated 189 with ester-linked D-ala residues, which confer a zwitterionic charge to the polymer 2, 43 .
As shown 190
in panels e and f of Fig. 3 , production and yield of EVs by the dltA mutant were similar to that of 191 the parental strain Newman. 192
To determine whether EV size was affected by reduced PGN crosslinking, the size 193 distribution of purified EVs was measured by dynamic light scattering (DSL). Treatment of JE2 194 cultures with 0.2 µg/ml PenG or mutation of pbp4 or tagO resulted in a significant increase in the 195 9 size distribution of EVs (Fig. 3g) , as well as an increased EV average size (Fig. 3h) 16 . 207
To determine whether PGN-hydrolases facilitate the release of EVs by altering the thick cell 208 wall of Gram positive bacteria, we compared EV production from atl and sle1 mutants with that of 209 strains JE2 and Newman. Although both mutants showed reduced EV production (Fig. 4a) , the 210 reduction in yield was only significant in the sle1 mutants (Fig. 4b) . Similar results were obtained 211 by nanoparticle tracking analysis wherein EV purification from the sle1 mutant, but not the atl 212 mutant, yielded a significantly lower EV concentration compared with that of the WT strain JE2 213 (Fig. 4c) . To determine whether autolysin activity affected the size distribution of EVs, we 214 evaluated purified EVs by dynamic light scattering. As shown in Fig. 4d and 4e, both atl and sle1 215 mutations exhibited a reduced EV size compared to WT JE2 EVs. 216
The influence of capsular polysaccharide (CP) on S. aureus EV production. Streptococcal 217 CP production was shown to hinder EV release by Streptococcus pneumoniae 7 but not 218 S. pyogenes 8 . To determine whether the presence of S. aureus CP impacted EV biogenesis, we 219 10 evaluated EV production by a number of isogenic CP+ and CP-strains. The EV pellet was derived 220 by ultracentrifugation of filter-sterilized culture supernatants and would not contain soluble CP. As 221 shown in Fig. 5a , the CP phenotype had no obvious impact on the EV dot blot signal derived from 222 WT or CP-mutants of strains Newman or 6850. Similarly, when we complemented the genetic 223 defect in the cap5 locus of USA300 strain 923 with pCap17, the strain produced CP5 46, 47 , but 224 there was no effect on the EV signal levels achieved by dot blotting (Fig. 5a) . Likewise, CP+ and 225 isogenic CP-strains of Newman, 6850, and 923 produced comparable protein yields of EVs (Fig.  226   5b) . Thus, S. aureus CP did not influence the yield or block the release of EVs from S. aureus 227 Newman (CP5+), 6850 (CP8+), or a CP5+ USA300 isolate. 228
To investigate whether CP antigens were associated with S. aureus EVs, we performed CP 229 immunoblots on EVs prepared from strains Newman (CP5+), MN8 (CP8+), and USA300 230 FPR3757 (CP-). We tested both intact and sonicated EVS since CP antibodies would react with 231 surface-associated CP antigens on intact EVs, whereas intravesicular CP antigens would only be 232 detected in sonicated EV preparations. Figure 5c shows that CP5 was only detected in sonicated, 233 but not intact Newman EVs, whereas CP8 was detected in both intact and sonicated MN8 EVs. 234
Because WT FPR3757 produces no CP, EVs from this strain reacted with neither CP antibody. 235
These data indicate both CP5 and CP8 were associated with EVs produced by CP+ S. aureus 236 isolates, although only CP8 was surface exposed. Additional studies outside the scope of this 237 report are needed to confirm and evaluate the prevalence, significance, and mechanism by which 238 CP is surface exposed on EVs prepared from a variety of S. aureus isolates. (Table S1 ). Thus, JE2 EVs could serve as a 242 multivalent S. aureus vaccine candidate if the toxicity of the EVs were eliminated. We detoxified 243 by using an antibody reactive with both LukS-PV and LukE subunits, we showed that only EVs 253 from WT JE2 had detectable leukocidin reactivity ( were detectable by LC-MS/MS in EVs purified from the JE2∆agr∆spa mutant (Table S2) . Although 260
LukAB was still present in EVs from JE2∆agr∆spa, there was ≥86% reduction in the number of 261 peptides detected in the mutant strain (Table S1 and Table S2 ). Moreover, as indicated below, 262
EVs recovered from the mutant strain showed no residual toxicity toward human leukocytes. 263
To investigate whether the detoxified JE2 EVs were immunogenic and protective against 264 infection, we immunized mice with 5 µg EVs from JE2∆agr or JE2∆agr∆spa mutants; control mice 265 were given PBS. EVs from either mutant elicited a serum antibody response against sonicated 266 WT EVs, although the antibody level elicited by ∆agr EVs was higher than that elicited by 267 ∆agr∆spa EVs (Fig. S2a) . To examine the antigen profiles from EVs that elicited antibody 268 responses after immunization, a bacterial lysate from the USA300 FPR3757 strain was subjected 269 to SDS-PAGE and immunoblotted with pooled sera from mice immunized with either ∆agr EVs or 270 12 ∆agr∆spa EVs. Notably, sera from ∆agr∆spa EVs-immunized mice reacted with more bacterial 271 antigens than sera from ∆agr EVs-immunized mice (Fig. S2b) , suggesting that ∆agr∆spa EVs 272 elicited a greater diversity of antibodies than ∆agr EVs. To further evaluate the protective efficacy 273 of EVs, the immunized mice were challenged with WT USA300 strain FPR3757. Immunization of 274 mice with EVs from JE2∆agr∆spa, but not EVs from JE2∆agr, provided significant protection 275 against lethal sepsis (Fig. S2c) . Preliminary studies indicated that immunization with higher doses 276 of EVs mixed with alum did not enhance immunogenicity (Fig. S2d) . 277
S. aureus engineered EVs (eng-EVs) elicit neutralizing antibodies and protect against 278
lethal sepsis. An ideal multicomponent S. aureus vaccine should elicit cytotoxin neutralizing 279
antibodies. Hla is a major secreted staphylococcal cytotoxin, and its production has been 280 associated with severe infections caused by community-acquired MRSA 53 . Immunization 281 against a nonpore-forming Hla variant (HlaH35L) prevents experimental S. aureus pneumonia, 282 skin abscesses, and lethal peritonitis [54] [55] [56] . To enhance the protective efficacy of detoxified EVs 283 from JE2∆agr∆spa, we engineered JE2 to package nontoxic HlaH35L 57 and the LukE monomer 284 within eng-EVs. LukED is a member of the S. aureus family of bicomponent leukotoxins and is 285 detected in 82% of blood isolates and 61% of nasal isolates 58 . LukED targets both human and 286 murine neutrophils, macrophages, T cells, dendritic cells, NK cells, and erythrocytes 59, 60 . 287
We expressed nontoxic HlaH35L and LukE in strain JE2∆agr∆spa under control of the spa 288 promoter. Because the activity of the spa promoter is enhanced in an ∆agr genetic background, 289 the mRNA levels of Hla H35L and LukE expressed in JE2∆agr∆spa were dramatically increased 290 compared to expression in JE2∆agr∆spa or JE2∆agr∆spa with the empty vector (Fig. S1c) . As 291 predicted, both HlaH35L and LukE were detected by Western blot in engineered EVs (eng-EVs) 292 isolated from recombinant strain JE2∆agr∆spa (pHlaH35L-LukE) (Fig. S1b) . 293
To evaluate the relative toxicity of EVs prepared from WT strain JE2 and JE2∆agr∆spa vs. 294 eng-EVs from JE2∆agr∆spa (pHlaH35L-LukE), we incubated the EVs in vitro with three different 295 13 cell types. A549 cells are susceptible to Hla-mediated cytolysis, and WT strain JE2 EVs were 296 toxic at concentrations as low as 1 µg/ml. In contrast, JE2∆agr∆spa mutant EVs and the eng-EVs 297 from JE2∆agr∆spa (pHlaH35L-LukE) exhibited negligible toxicity (Fig. S3a) . HL60 cells are resistant 298
to Hla-mediated lysis, but they are susceptible to the cytolytic activity of the S. aureus leukocidins 299 (including HlgAB, HlgCB, PVL-SF, LukED, LukAB, and phenol soluble modulins [PSMs]). EVs 300 isolated from strain JE2, but not the ∆agr∆spa mutant or eng-EVs, were cytolytic for HL60 cells 301 at concentrations as low as 1 µg/ml (Fig. S3b) . Rabbit erythrocytes are susceptible to Hla, PSMs, 302 and the leukocidins HlgAB and LukED 61, 62 . EVs isolated from WT strain JE2 exhibited significant 303 hemolytic activity at concentrations as low as 1 µg/ml, but no hemolytic activity resulted from EVs 304 prepared from the ∆agr∆spa mutant or eng-EVs, even at 20 µg/ml (Fig. S3c) . These data 305 demonstrate that the eng-EVs were nontoxic in vitro for mammalian cells. 306
We immunized mice on days 0. 14, and 28 with 5 µg EVs from JE2∆agr or JE2∆agr∆spa 307 mutants; control mice were given 5 ug bovine serum albumin (BSA). Whereas sera from mice 308 immunized with both eng-EVs and ∆agr∆spa EVs, but not BSA, reacted by ELISA with sonicated 309 WT JE2 EVs (Fig. 6a) , only mice given the eng-EVs responded with antibodies to purified Hla 310 (Fig. 6b) or LukE (Fig. 6c) . These data indicate that recombinant proteins packaged within 311
S. aureus EV are immunogenic. 312
To examine whether the antibodies elicited in mice by the eng-EV vaccine were functional, 313 toxin neutralizing assays were performed. Sera from mice immunized with eng-EVs effectively 314 neutralized Hla at dilutions ranging from 1:20 to 1:80 (Fig. 6d) . In contrast, neutralizing antibodies 315 were low or undetectable in serum from mice given BSA or ∆agr∆spa EVs. Similarly, sera from 316 mice immunized with eng-EVs, but not BSA or ∆agr∆spa EVs, were able to effectively neutralize 317
LukED at dilutions ranging from 1:10 to 1:20 (Fig. 6e) . Sera from mice immunized with eng-EVs 318 also neutralized leukocidin HlgAB (Fig. 6f) , but not PVL-SF or HlgCB leukotoxins. 319
The immunized mice were challenged with USA500 strain NRS685, a PVL-negative MRSA 320 14 bacteremia isolate. We chose this strain because the PVL-S and PVL-F subunits can interact with 321
LukE and LukD to form inactive hybrid complexes, and this influences LukED-mediated S. aureus 322 virulence in mice 63 . As shown in Fig. 6g, immunization The S. aureus cell envelope is comprised of a thick, highly cross-linked PGN layer, 359 proteins, and glycopolymers like WTA and CP. When we assessed the role of the PGN layer on 360 EV release, we found that highly crosslinked PGN serves as a barrier for EV biogenesis. 361
Treatment of S. aureus with sublethal concentration of penicillin G or genetic inactivation of pbp4 362
or tagO, which result in reductions in PGN cross-linking, resulted in a significant increase in EV 363 production, as well as the average size of released EVs. This inverse correlation between PGN 364 cross-linking and EV yield was not unique to USA300 strain JE2 but was also observed with 365 S. aureus strains MW2, COL, and Newman. WTA has been shown to be critical for PGN-366 crosslinking by regulating PBP4 localization to the septation site 42 . A secondary mechanism by 367 which WTA regulates EV production is via its ability to control the activity of Atl and Sle1 -not only . Whereas Sle1 could be visualized over 394 the entire septal surface, Atl localized only at the external (surface-exposed) edge of the 395 septum 77 . How autolysins modulate EV release from the cell wall or whether this process is 396 spatially or temporally regulated remains to be determined. 397
Newman and MN8 in our study. We reported that S. aureus CP was shed from broth-grown 399
S. aureus cells 78
, and it is feasible that EVs could serve as a vehicle to liberate CP from the cell 400 envelope. The S. pneumonia capsule was reported to hinder EV release in this pathogen 7 , 401 whereas no effect was observed on EV yield in strains with or without the hyaluronic capsule of 402 with JE2∆agr∆spa EVs showed a significant reduction in lethality provoked by WT USA300 strain 431 FPR3757 compared to mice given PBS or JE2∆agr EVs. 432
S. pyogenes
To enhance the protective efficacy of ∆agr∆spa EVs as a vaccine platform, nontoxic 433
HlaH35L and LukE were expressed in JE2∆agr∆spa under the control of the agr-derepressed spa 434 promoter. Immunization with purified nontoxic HlaH35L prevents lethal pneumonia and lethal 435 peritonitis and reduces the incidence of necrotic skin abscesses [54] [55] [56] . S. aureus leukocidins 436 comprise a family of pore-forming toxins produced by S. aureus that target monocytes, 437 lymphocytes, neutrophils, and macrophages -the very cells responsible for resolution of bacterial 438 infection. These "eng-EVs" elicited antibodies in the sera of immunized mice that reacted with Hla 439 and LukE by ELISA and neutralized the cytolytic activity of Hla, LukED, and HlgAB in vitro. 440
Mice immunized with eng-EVs, ∆agr∆spa EVs, or BSA were challenged with USA500 441 strain NRS685, a PVL-negative MRSA bacteremia isolate. LukED has been shown to enhance 442 lethality in mice challenged with S. aureus In summary, we have generated, purified, and characterized EVs isolated from S. aureus 453 USA300, the predominant CA-MRSA clone in United States. Our study revealed that S. aureus 454
PSMs are central for EVs generation by targeting the cytoplasmic membrane. Likewise, the Sle1 455 autolysin is critical for the release of EVs from S. aureus cell wall. Whereas mutations in Atl or 456 CP production did not affect EV yield, PBP4 and WTA promote PGN cross-linking and 457 consequently diminished EV production. Our study elucidates certain mechanisms whereby 458 S. aureus produces and sheds EVs (Fig. 7) and will ultimately further our understanding of 459 bacterial physiology and pathogenesis. We designed and created eng-EVs as a novel vaccine 460 platform against S. aureus infection. Detoxified EVs that over-produced HlaH35L and LukE were 461 immunogenic, elicited toxin neutralizing antibodies, and protected mice in a S. aureus lethal 462 sepsis model, indicating that these naturally produced vesicles have potential as a noval vaccine 463
platform. 464
Materials and Methods 465
Bacterial strains and plasmids. S. aureus isolates (listed in Table S3) , rendering it sensitive to Em. The agr mutation (∆agr::tetM) was transduced from 474
S. aureus RN6911
86 to wild-type (WT) JE2 using bacteriophage ϕ80α with selection for Tet 475 resistance. To construct the JE2 ∆agr∆spa double mutant, the spa mutation was transduced from 476 JE2 (spa::ermB) to JE2∆agr by ϕ80α transduction. The pbp4 mutation was transduced from JE2 477 (∆pbp4::ermB) to WT MW2 and COL by ϕ80α transduction with selection for Em resistance. All 478 mutants were confirmed by PCR using the primers listed in Table S4 . ELISA results confirmed 479 the phenotype of the ∆spa mutant, and the agr mutants lost their hemolytic phenotype. To 480 construct the WTA mutants, the tagO mutation was transduced from SA113 ∆tagO (pRBtagO) to 481 WT JE2 and COL with ϕ80α with selection for Em resistance. Mutants were confirmed by PCR 482 and acquisition of resistance to lysis by ϕ80α. 483
To construct a shuttle vector for expression of HlaH35L and LukE, the spa promoter, hlaH35L, 484
and lukE genes were amplified from S. aureus strains JE2, DU1090 (pHlaH35L), and FRP3757, 485 respectively. To drive the expression of hlaH35L, its sequence was fused to the 3' terminus of the 486 spa promoter containing the ribosome binding site by overlapping PCR. The Pspa-hlaH35L fusion 487 sequence was cloned into the shuttle plasmid pCU1 with restriction enzymes HindIII and SalI. 488
The amplified lukE sequence containing a ribosome binding site was inserted into pCU1 with 489 restriction enzymes SalI and EcoRI. The resulting plasmid pCU1-Pspa-hlaH35L-lukE was verified by 490 enzyme digestion and DNA sequencing. To construct JE2∆spa∆agr expressing nontoxic HlaH35L 491
and LukE, pCU1-Pspa-hlaH35L-lukE was transformed into RN4220 by electroporation and then 492 transduced with ϕ80α to JE2∆spa∆agr, selecting for Cm resistance. 493
21
Isolation and purification of EVs. Isolation of EVs from S. aureus was performed as previously 494 described 7,16 with minor modifications. S. aureus was cultivated in TSB with shaking to an OD650 nm 495 of 1.2. The culture supernatant was filtered and concentrated 25-fold with a 100-kDa tangential 496 flow filtration system (Pall Corp.). The retentate was filtered again before centrifugation at 497 150,000 g for 3 h at 4°C to pellet the vesicles and leave soluble proteins in the supernatant. The 498 EV pellet was suspended in 40% Optiprep density gradient medium (Sigma) and overlaid with 499 gradient layers of Optiprep ranging from 35% to 10%. After centrifugation at 139,000 g for 16 h at 500 4°C, 1 ml fractions were removed sequentially from the top of the gradient. Each fraction was 501 subjected to SDS-PAGE and stained with a Thermo Fisher silver staining kit. Fractions with a 502 similar protein profile on SDS-PAGE were pooled, and the Optiprep medium was removed by 503 diafiltration with phosphate-buffered saline (PBS; 10 mM Na2HPO4, 2 mM KH2PO4, 2.7 mM KCl, 504 and 137 mM NaCl, pH 7.4) using an Amicon Ultra-50 Centrifugal Filter Unit. The diafiltered 505 retentate was filtered (0.45 µm) and stored at 4°C. EV protein concentrations were determined by 506 using a Protein Assay Dye Reagent (Bio-Rad). The size distribution and diameter of vesicles was 507 measured using a ZetaPALS dynamic light scattering detector (Brookhaven Instruments Corp.). 508
Nanoparticle tracking analysis (NTA) was performed by purifying EVs from 100 ml bacterial 509 cultures, as described above. The number of EV particles recovered from individual cultures (and 510 suspended in 1 ml PBS) was determined using a Nanosight NS300 Sub Micron Particle Imaging 511 System (Malvern), as previously described 87 . 512
Electron microscopy of S. aureus EVs. Five microliters of S. aureus EVs were adsorbed for 513 1 min to a carbon coated grid that was made hydrophilic by a 30-sec exposure to a glow discharge. 514
The samples were stained with 0.75% uranyl formate for 30 sec and examined in a JEOL 1200EX 515 Real time RT-PCR assay. S. aureus strains were cultivated in 5 ml TSB at 37°C to an OD650 nm 527 of 0.9. After centrifugation at 4°C, the bacterial cells were mixed with glass beads in 300 µl lysis 528 buffer (RNeasy mini kit; Qiagen) and lysed by using a high speed Ultramat 2 Amalgamator (SDI, 529
Inc.). Total RNA from the lysate supernatant was purified with the RNeasy mini kit (Qiagen), 530 treated with DNase I (Invitrogen), and stored at -70°C. cDNA was synthesized from 1 µg of 531 bacterial RNA using a Protoscript II First Strand cDNA synthesis kit (New England Biolabs). 50 532 ng of synthesized cDNA was subjected to Real-time RT-PCR using a Power Green PCR Master 533 Mix (Applied Biosystems) with primers listed in Table S4 and detected in a StepOnePlus Real-534
Time PCR System (Applied Biosystems). The relative transcriptional levels of hlaH35L and lukE 535 were calculated using the ∆∆Ct method by normalizing to the 16s rRNA transcriptional level. 536
Immunoblotting assays. For Western blots, 10 µg S. aureus EVs were subjected to SDS-PAGE, 537 transferred to nitrocellulose membranes, and blocked with PBS + 0.05% Tween-20 (PBST) and 538 1% skim milk for 1 h at room temperature (RT). After washing with PBST, the membranes were 539 incubated with rabbit anti-LukS-PV (IBT Bioservices) or mouse anti-Hla monoclonal antibody 540 For EV dot blotting assays, intact or sonicated EVs were applied to nitrocellulose 546 membranes using a 96 well dot blotter system (Bio-Rad). To block the staphylococcal IgG binding 547 proteins Spa and Sbi, the membranes were blocked with PBST + 5% skim milk and incubated 548 overnight at 4°C with an irrelevant human IgG1 monoclonal antibody (10 µg/ml) in PBST + 1% 549 skim milk. The membrane was washed with PBST and incubated overnight at 4°C with sera 550 (diluted 1:1000 in PBST + 1% skim milk) pooled from mice immunized with EVs (see below) or 551 murine mAbs 78 to CP5 (4C2; 1.2 µg/ml) or CP8 (5A6; 1.2 µg/ml). After washes with PBST, the 552 membrane was incubated with alkaline phosphatase (AP)-conjugated goat anti-mouse antibody 553
(1:15000 dilution in PBST + 1% skim milk) at RT for 2 h. The membrane was washed with PBST 554 and developed with AP membrane substrate (KPL). 555 EV cytotoxicity. The relative toxicity of S. aureus EVs (1 to 20 µg/ml) toward human A549 lung 556 epithelial cells, neutrophil-like HL60 cells, and rabbit erythrocytes was assessed. A549 lung 557 epithelial cells grown in a 96-well plate were incubated overnight at 37°C with EVs or 1 µg/ml of 558 purified Hla. Toxicity was assessed using an LDH cytotoxicity assay kit (ThermoFisher Scientific). CellTiter kit (Promega). A 2% rabbit erythrocyte suspension was mixed with EVs or 1 µg/ml Hla 562 in a 96-well plate for 1 h at 37°C. The erythrocytes were pelleted by centrifugation, and hemolysis 563 was recorded by measuring the OD545 nm of the supernatant using an ELISA reader. were immunized similarly with bovine serum albumin (BSA; Sigma). Blood was collected from the 571 mice by tail vein puncture before each vaccination and again before challenge. Sera were diluted 572 1:100 and tested by ELISA on 96-well plates coated with 5 µg/ml sonicated WT EVs, 5 µg/ml 573 LukE, or 1 µg/ml Hla. Immunized mice were inoculated with ~2 x 10 8 CFU S. aureus by 574 intravenous (IV) tail vein injection two weeks after the third vaccination. Survival was monitored 575 up to 14 days post-challenge, and the data were analyzed using the log-rank test. 576
Toxin neutralization assays (TNAs). For Hla TNAs, the assay was performed as we previously 577 Women's Hospital (Human Subject Assurance Number 00000484). Neutrophils were isolated 580 from 10 ml human blood using Polymorphprep (Accurate Chemical), washed, and suspended in 581 RPMI (Invitrogen) containing 5% fetal bovine serum (Invitrogen). Sera from immunized mice were 582 serially diluted and mixed with toxin concentrations yielding ~75% cell lysis (12.5 µg/ml LukED, 583 2.5 µg/ml PVL, 1 µg/ml HlgAB, or 2 µg/ml HlgCB (1∶1 S and F subunits). Samples were pre-584 incubated with leukocidins for 30 min at RT before the addition of neutrophils (1.2×10 5 cells). After 585 2 h at 37°C in 5% CO2, the cells were harvested by centrifugation and suspended in fresh medium. 586
Cell viability was evaluated using CellTiter kit (Promega) according to the manufacturer's 587 recommendations. Percent neutralization was calculated using the formula: [% Viability of (serum 588 + leukocidin + neutrophils) -% Viability of (leukocidin + neutrophils)]. 589
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